Search

Un bénéfice clinique durable a été obtenu avec l’association nivolumab (NIVO)+ipilimumab (IPI), dont une survie globale (SG) de 49 % et une survie spécifique liée au mélanome (SSM) de 56 %, sans atteindre la SSM médiane après un suivi minimum de 6,5 ans. Nous rapportons ici des résultats montrant que l’efficacité se maintient à 7,5 ans.

A 32-year-old female presented with a right ovarian mass, and the unilateral oophorectomy specimen revealed adenocarcinoma with signet-ring cells histology consistent with a Krukenberg tumor. The high-grade gastric primary adenocarcinoma was later identified, but by this time a viable 7-week fetus and left ovarian Krukenberg tumor were present. Second trimester palliative oophorectomy and partial gastrectomy were performed. The patient delivered a healthy infant by cesarean section and is now 36 months after the initial diagnosis of metastatic gastric carcinoma and remains asymptomatic and free of disease. The unexpectedly favorable clinical outcome suggests that a patient may benefit from resection of gastric adenocarcinoma metastatic to ovary when other sites of metastatic disease are not evident.

Dans le cadre de l’essai CheckMate 067, l’association de nivolumab (NIVO, anti-PD-1) et d’ipilimumab (IPI, anti-CTLA-4) a amélioré de manière significative la survie sans progression médiane (SSPm) et le taux de réponse objective (TRG) par rapport à l’IPI seul chez des patients atteints de mélanome avancé. Nous rapportons les résultats d’efficacité et de sécurité d’emploi mis à jour de cette étude.

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.